Q4 Earnings Estimate for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Research analysts at Leerink Partnrs cut their Q4 2025 earnings per share (EPS) estimates for shares of Illumina in a research report issued to clients and investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will post earnings of $1.24 per share for the quarter, down from their prior estimate of $1.25. The consensus estimate for Illumina’s current full-year earnings is $4.11 per share. Leerink Partnrs also issued estimates for Illumina’s FY2026 earnings at $4.90 EPS.

ILMN has been the topic of a number of other research reports. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. Royal Bank of Canada increased their price objective on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Robert W. Baird boosted their target price on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group upped their price target on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $165.95.

Illumina Stock Up 0.3 %

Illumina stock opened at $139.08 on Wednesday. Illumina has a twelve month low of $100.08 and a twelve month high of $156.66. The stock has a market cap of $22.06 billion, a P/E ratio of -13.96 and a beta of 1.11. The company’s 50-day moving average price is $141.62 and its two-hundred day moving average price is $131.98. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.33 earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in shares of Illumina by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after purchasing an additional 48,018 shares during the last quarter. Primecap Management Co. CA grew its stake in shares of Illumina by 3.6% during the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after buying an additional 87,599 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after buying an additional 625,245 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Illumina by 305.0% during the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after buying an additional 1,118,747 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Illumina by 4.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock valued at $164,334,000 after acquiring an additional 54,319 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.